Completed × Has results × Breast Neoplasms, Male × Clear all Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Phase 1 Completed
16 enrolled 10 charts
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Phase 2 Completed
454 enrolled 23 charts
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Phase 3 Completed
305 enrolled 10 charts
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Phase 2 Completed
58 enrolled 16 charts
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
Phase 3 Completed
3,649 enrolled 17 charts
PePPy
Phase 2 Completed
40 enrolled 26 charts
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Phase 1/2 Completed
51 enrolled 13 charts
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Phase 3 Completed
213 enrolled 16 charts
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Phase 2 Completed
30 enrolled 15 charts
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Phase 2 Completed
122 enrolled 22 charts
Bicalutamide in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
28 enrolled 10 charts
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Phase 1 Completed
7 enrolled 8 charts
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Phase 2 Completed
468 enrolled 16 charts
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Phase 2 Completed
304 enrolled 12 charts
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Phase 1/2 Completed
60 enrolled 6 charts
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Phase NA Completed
7 enrolled 7 charts
Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery
Phase 2 Completed
50 enrolled 10 charts
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Phase NA Completed
13 enrolled 43 charts
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Phase NA Completed
15 enrolled 10 charts
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Phase 2 Completed
57 enrolled 8 charts
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Phase 2 Completed
30 enrolled 6 charts
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase 1/2 Completed
25 enrolled 14 charts
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Phase NA Completed
8 enrolled 10 charts
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Phase 2 Completed
68 enrolled 10 charts
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
63 enrolled 8 charts
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase 1/2 Completed
15 enrolled 13 charts
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Phase 2 Completed
20 enrolled 6 charts
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 1/2 Completed
48 enrolled 14 charts
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Phase NA Completed
28 enrolled 16 charts
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
36 enrolled 11 charts
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Phase 2 Completed
46 enrolled 11 charts
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
48 enrolled 10 charts
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
Phase 2 Completed
30 enrolled 10 charts
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase 1/2 Completed
11 enrolled 16 charts
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Completed
44 enrolled 10 charts
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Phase 2 Completed
15 enrolled 11 charts
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Phase 2 Completed
19 enrolled 6 charts
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Phase 1/2 Completed
30 enrolled 13 charts
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Phase 2 Completed
50 enrolled 11 charts
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Phase NA Completed
41 enrolled 12 charts
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
Phase 2 Completed
85 enrolled 18 charts
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Completed
28 enrolled 13 charts
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Phase 1/2 Completed
23 enrolled 9 charts
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Phase 2 Completed
95 enrolled 7 charts
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
50 enrolled 11 charts
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2 Completed
47 enrolled 8 charts
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Completed
31 enrolled 10 charts
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Phase 2 Completed
32 enrolled 6 charts
Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Phase NA Completed
39 enrolled 6 charts
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
Phase 2 Completed
39 enrolled 7 charts